Epizyme, Inc.

NasdaqGS:EPZM Lagerbericht

Marktkapitalisierung: US$247.5m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Epizyme Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Grant Bogle

Geschäftsführender

US$3.0m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts9.9%
Amtszeit als Geschäftsführerless than a year
Eigentum des Geschäftsführersn/a
Durchschnittliche Amtszeit des Managements2.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder10.2yrs

Jüngste Management Updates

Recent updates

Epizyme GAAP EPS of -$0.21, revenue of $27.5M

Aug 09

Epizyme Acquisition By Ipsen: CVR Value

Jul 05

Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates

May 16
Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates

Epizyme: Taking Advantage Of Recent Sell-Off

Nov 25

Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?

Sep 14
Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?

Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts

Aug 10
Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts

Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge

Jun 22

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Jun 08
Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Epizyme gains as peer Constellation attracts sizable premium from MorphoSys

Jun 02

Epizyme, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%

Feb 25
Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Jan 16
Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Epizyme says Boehringer terminates collaboration agreement

Dec 24

Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?

Dec 12
Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?

Epizyme Q3 2020 Earnings Preview

Nov 05

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Grant Bogle im Vergleich zu den Einnahmen von Epizyme verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Jun 30 2022n/an/a

-US$208m

Mar 31 2022n/an/a

-US$236m

Dec 31 2021US$3mUS$299k

-US$251m

Sep 30 2021n/an/a

-US$267m

Jun 30 2021n/an/a

-US$257m

Mar 31 2021n/an/a

-US$251m

Dec 31 2020US$196kn/a

-US$232m

Sep 30 2020n/an/a

-US$222m

Jun 30 2020n/an/a

-US$202m

Mar 31 2020n/an/a

-US$192m

Dec 31 2019US$309kn/a

-US$173m

Vergütung im Vergleich zum Markt: Grant's total compensation ($USD3.01M) is above average for companies of similar size in the US market ($USD1.66M).

Entschädigung vs. Einkommen: Grant's compensation has increased whilst the company is unprofitable.

Geschäftsführer

Grant Bogle (64 yo)

less than a year

Amtszeit

US$3,011,807

Vergütung

Mr. Grant C. Bogle has been Chief Executive Officer, President and Director at Epizyme, Inc. since August 9, 2021 and serves as Principal Financial Officer since November 1, 2021 and served as its Independ...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Grant Bogle
Presidentless than a yearUS$3.01mkeine Daten
Jeffery Kutok
Chief Scientific Officer2.3yrsUS$2.86m0.0080%
$ 19.9k
H. Horvitz
Co-Founder & Chairman of the Scientific Advisory Boardno datakeine Datenkeine Daten
Yi Zhang
Scientific Co-Founder & Member of The Scientific Advisory Boardno datakeine Datenkeine Daten
Jerald Korn
Chief Operating Officerless than a yearkeine Datenkeine Daten
Joseph Beaulieu
Senior VP4.1yrskeine Daten0.0058%
$ 14.3k
Craig West
Vice President of Investor Relationsno datakeine Datenkeine Daten
John Weidenbruch
Senior VPno datakeine Datenkeine Daten
Tanja Weber
Chief Business Officer3.6yrskeine Datenkeine Daten
Mark De Rosch
Chief Regulatory Officer2.8yrskeine Datenkeine Daten
Rebecca Mehrwerth
Senior VP & Head of Commercialless than a yearkeine Datenkeine Daten
Christoph Diefenbach
Laboratory Manager of Research & Developmentno datakeine Datenkeine Daten

2.3yrs

Durchschnittliche Betriebszugehörigkeit

56.5yo

Durchschnittliches Alter

Erfahrenes Management: EPZM's management team is considered experienced (2.3 years average tenure).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Grant Bogle
President2.9yrsUS$3.01mkeine Daten
H. Horvitz
Co-Founder & Chairman of the Scientific Advisory Boardno datakeine Datenkeine Daten
Yi Zhang
Scientific Co-Founder & Member of The Scientific Advisory Boardno datakeine Datenkeine Daten
George Daley
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten
David Mott
Independent Chairman12.7yrsUS$370.00k0.19%
$ 474.0k
Carl Goldfischer
Independent Director12.9yrsUS$350.00k0.0030%
$ 7.4k
Christopher Walsh
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten
Kenneth Bate
Independent Director7.7yrsUS$330.94k0%
$ 0
Bruce Chabner
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten
Ronald Evans
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten
Joel Huff
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten
Steven Henikoff
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten

10.2yrs

Durchschnittliche Betriebszugehörigkeit

68yo

Durchschnittliches Alter

Erfahrener Vorstand: EPZM's board of directors are seasoned and experienced ( 10.2 years average tenure).